Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue

British Journal of Pharmacology

Volumn 169, Issue 6, 2013, Pages 1322-1334

  Varkevisser, R ^a   Houtman, M J C ^a   Linder, T ^b   De Git, K C G ^a   Beekman, H D M ^a   Tidwell, R R ^c   Ijzerman, A P ^d   Stary Weinzinger, A ^b   Vos, M A ^a   Van Der Heyden, M A G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

chemical substructures; dofetilide; drug induced trafficking defects; hERG; ion channel trafficking; KIR2.1; Long QT syndrome; pentamidine; safety pharmacology

Indexed keywords

DELAYED RECTIFIER POTASSIUM CHANNEL; DOFETILIDE; DOFETILIDE DERIVATIVE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; ION CHANNEL; PENTACRIT 300; PENTAMIDINE; PENTAMIDINE DERIVATIVE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; CELL LEVEL; CELL STRAIN HEK293; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIPROTOZOAL AGENTS; ARRHYTHMIAS, CARDIAC; CELL MEMBRANE; DOGS; ENDOCYTOSIS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; KINETICS; MEMBRANE TRANSPORT MODULATORS; MICE; MOLECULAR DYNAMICS SIMULATION; PENTAMIDINE; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; RECOMBINANT PROTEINS; SHAB POTASSIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84879366417     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12208     Document Type: Article

References (60)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, et al. (2006). Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113: 365-373.
3. Bakunova SM, Bakunov SA, Patrick DA, Kumar EV, Ohemeng KA, Bridges AS, et al. (2009a). Structure-activity study of pentamidine analogues as antiprotozoal agents. J Med Chem 52: 2016-2035.
4. Bakunova SM, Bakunov SA, Wenzler T, Barszcz T, Werbovetz KA, Brun R, et al. (2009b). Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine. J Med Chem 52: 4657-4667.
5. Balijepalli SY, Anderson CL, Lin EC, January CT, (2010). Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes. J Cardiovasc Pharmacol 56: 113-122.
6. Bibler MR, Chou TC, Toltzis RJ, Wade PA, (1988). Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94: 1303-1306.
7. de Boer TP, van Veen TA, Houtman MJ, Jansen JA, van Amersfoorth SC, Doevendans PA, et al. (2006). Inhibition of cardiomyocyte automaticity by electrotonic application of inward rectifier current from Kir2.1 expressing cells. Med Biol Eng Comput 44: 537-542.
8. de Boer TP, Nalos L, Stary A, Kok B, Houtman MJ, Antoons G, et al. (2010). The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel. Br J Pharmacol 159: 1532-1541.
9. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, et al. (2010). AMBER 11. University of California: San Francisco, CA.
10. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. (2012). Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12-18.
11. Cohen FE, Kelly JW, (2003). Therapeutic approaches to protein-misfolding diseases. Nature 426: 905-909.
12. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, et al. (2005). Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145: 15-23.
13. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT, (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803.
14. Dennis AT, Wang L, Wan H, Nassal D, Deschenes I, Ficker E, (2012). Molecular determinants of pentamidine-induced hERG trafficking inhibition. Mol Pharmacol 81: 198-209.
15. Dessertenne F, (1966). [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 59: 263-272.
16. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. (2004). Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15: 475-495.
17. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC, (2004). Physicochemical features of the HERG channel drug binding site. J Biol Chem 279: 10120-10127.
18. Ficker E, Obejero-Paz CA, Zhao S, Brown AM, (2002). The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem 277: 4989-4998.
19. Ficker E, Dennis AT, Wang L, Brown AM, (2003). Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92: e87-100.
20. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, et al. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44.
21. Frisch MJ, Trucks CW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. (2009). Gaussian 09. Gaussian, Inc.: Wallingford, CT.
22. Girgis I, Gualberti J, Langan L, Malek S, Mustaciuolo V, Costantino T, et al. (1997). A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 112: 646-653.
23. GOLD (2008). GOLD, version 4.0: Cambridge Crystallographic Data Centre; Cambridge, UK.
24. Gong Q, Jones MA, Zhou Z, (2006). Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. J Biol Chem 281: 4069-4074.
25. Han S, Zhang Y, Chen Q, Duan Y, Zheng T, Hu X, et al. (2011). Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking. Eur J Pharmacol 650: 138-144.
26. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47: 219-233.
27. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008). GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447.
28. van der Heyden MA, Smits ME, Vos MA, (2008). Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153: 406-409.
29. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C, (2006). Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
30. Jha TK, (1983). Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 77: 167-170.
31. Jones SK, Hall JE, Allen MA, Morrison SD, Ohemeng KA, Reddy VV, et al. (1990). Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 34: 1026-1030.
32. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983). Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
33. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC, (2006). Molecular determinants of HERG channel block. Mol Pharmacol 69: 1709-1716.
34. Kannankeril P, Roden DM, Darbar D, (2010). Drug-induced long QT syndrome. Pharmacol Rev 62: 760-781.
35. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN, (2006). Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316: 1098-1106.
36. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
37. Knape K, Linder T, Wolschann P, Beyer A, Stary-Weinzinger A, (2011). In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel. Plos ONE 6: e28778.
38. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, et al. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-323.
39. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ, (2000a). Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57: 367-374.
40. Lees-Miller JP, Duan Y, Teng GQ, Thorstad K, Duff HJ, (2000b). Novel gain-of-function mechanism in K(+) channel-related long-QT syndrome: altered gating and selectivity in the HERG1 N629D mutant. Circ Res 86: 507-513.
41. Loo TW, Clarke DM, (1997). Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272: 709-712.
42. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
43. Nalos L, de Boer TP, Houtman MJ, Rook MB, Vos MA, van der Heyden MA, (2011). Inhibition of lysosomal degradation rescues pentamidine-mediated decreases of K(IR)2.1 ion channel expression but not that of K(v)11.1. Eur J Pharmacol 652: 96-103.
44. Pearlstein R, Vaz R, Rampe D, (2003). Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 46: 2017-2022.
45. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al. (2006). Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481-489.
46. Roden DM, Viswanathan PC, (2005). Genetics of acquired long QT syndrome. J Clin Invest 115: 2025-2032.
47. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
48. Shagufta GD, Guo D, Klaasse E, de Vries H, Brussee J, Nalos L, et al. (2009). Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues. ChemMedChem 4: 1722-1732.
49. Siu SW, Vacha R, Jungwirth P, Bockmann RA, (2008). Biomolecular simulations of membranes: physical properties from different force fields. J Chem Phys 128: 125103.
50. Stary A, Wacker SJ, Boukharta L, Zachariae U, Karimi-Nejad Y, Aqvist J, et al. (2010). Toward a consensus model of the hERG potassium channel. ChemMedChem 5: 455-467.
51. Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, et al. (2008). Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 153: 439-447.
52. Thomsen MB, Volders PG, Stengl M, Spatjens RL, Beekman JD, Bischoff U, et al. (2003). Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 307: 776-784.
53. Tidwell RR, Jones SK, Geratz JD, Ohemeng KA, Cory M, Hall JE, (1990). Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J Med Chem 33: 1252-1257.
54. Varkevisser R, Houtman MJ, Waasdorp M, Man JC, Heukers R, Takanari H, et al. (2013). Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine. Pflugers Arch 465: 247-259.
55. Warmke JW, Ganetzky B, (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A 91: 3438-3442.
56. Wharton JM, Demopulos PA, Goldschlager N, (1987). Torsade de pointes during administration of pentamidine isethionate. Am J Med 83: 571-576.
57. Winckels SK, Thomsen MB, Oosterhoff P, Oros A, Beekman JD, Attevelt NJ, et al. (2007). High-septal pacing reduces ventricular electrical remodeling and proarrhythmia in chronic atrioventricular block dogs. J Am Coll Cardiol 50: 906-913.
58. Wolf MG, Hoefling M, Aponte-Santamaria C, Grubmuller H, Groenhof G, (2010). g-membed: efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation. J Comput Chem 31: 2169-2174.
59. Zhou Z, Gong Q, Epstein ML, January CT, (1998). HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem 273: 21061-21066.
60. Zhou Z, Gong Q, January CT, (1999). Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 274: 31123-31126. FP7/2007-2013